PARPi is used as a targeted therapy for treating breast cancer susceptibility gene 1/2 (BRCA1/2)-mutant tumors by causing S-phase-specific DNA damage, which these cells cannot cope with due to their homologous recombination (HR) repair deficiency15–17. The gene discussed is BRCA1; the disease is breast carcinoma.